Nicholas Antos

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

Nicole Mayer-Hamblett, Félix Ratjen, Renee Russell et al. · The Lancet Respiratory Medicine · 2022 · 126 citations · Full text

Pharmacy, Pharmacotherapy, Good Clinical Practice +8

Creation and implementation of SAMPRO™: A school-based asthma management program

Robert F. Lemanske, Sujani Kakumanu, Kathleen Shanovich et al. · Journal of Allergy and Clinical Immunology · 2016 · 93 citations · Full text

Nursing, Pediatrics, School Nursing +13

Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients

Amir Moheet, Daniel Beisang, Lin Zhang et al. · Journal of Cystic Fibrosis · 2020 · 57 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +14

Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study

Patrick A. Flume, Reta Fischer Biner, D.G. Downey et al. · The Lancet Respiratory Medicine · 2021 · 51 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Refinement of newborn screening for cystic fibrosis with next generation sequencing

Michael J. Rock, Mei Baker, Nicholas Antos et al. · Pediatric Pulmonology · 2022 · 33 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17